Key result
Amlodipine combined with iron chelation therapy improved cardiac T2 by 2.79 ms compared to control group.
Why the study?
Iron overload cardiomyopathy causes significant morbidity and mortality in transfusion-dependent thalassemia, and standard iron chelation therapy is less efficient in alleviating organ iron accumulation.
Does adding amlodipine to standard iron chelation therapy improve cardiac T2 and myocardial iron concentration in pediatric patients with transfusion-dependent thalassemia?
Meta-Analysis (n=144)
Does adding amlodipine to standard iron chelation therapy improve cardiac T2 and myocardial iron concentration in pediatric patients with transfusion-dependent thalassemia?
Adding amlodipine to standard iron chelation therapy significantly improves surrogate markers of cardiac iron overload (cardiac T2 and myocardial iron concentration) in pediatric patients with transfusion-dependent thalassemia without increasing adverse events.
Answers are grounded in this paper and cite their sources.
Supports adjunctive amlodipine with chelation to improve cardiac iron markers in pediatric thalassemia; extends RCT evidence on surrogates.
BACKGROUND Iron overload cardiomyopathy is a significant cause of morbidity and mortality in transfusion-dependent thalassemia patients. Standard iron chelation therapy is less efficient in alleviating iron accumulation in many organs, especially when iron enters the cells via specific calcium channels. AIM To validate our hypothesis that adding amlodipine to the iron chelation regimen is more efficient in alleviating myocardial iron overload. METHODS Five databases, including PubMed, Cochrane Library, Embase, ScienceDirect, and ClinicalTrials.gov, were systematically searched, and three randomized controlled trials involving 144 pediatric patients with transfusion-dependent thalassemia were included in our meta-analysis based on the predefined eligibility criteria. The quality of the included studies was assessed based on the Cochrane collaboration tool for bias assessment. The primary outcome assessed was myocardial-T2 and myocardial iron concentration, while the secondary results showed serum ferritin level, liver iron concentration, and treatment adverse outcomes. Weighted mean difference and odds ratio were calculated to measure the changes in the estimated treatment effects. RESULTS During the follow-up period, Amlodipine treatment significantly improved cardiac T2 by 2.79 ms compared to the control group [95% confidence interval (CI): 0.34-5.24, P = 0.03, I 2 = 0%]. Additionally, a significant reduction of 0.31 in myocardial iron concentration was observed with amlodipine treatment compared to the control group [95%CI: -0.38-(-0.25), P < 0.00001, I 2 = 0%]. Liver iron concentration was slightly lower in the amlodipine group by -0.04 mg/g, but this difference was not statistically significant (95%CI: -0.33-0.24, P = 0.77, I 2 = 0%). Amlodipine also showed a non-significant trend toward a reduction in serum ferritin levels (-328.86 ng/mL, 95%CI: -1212.34-554.62, P = 0.47, I 2 = 90%). Regarding safety, there were no significant differences between the groups in the incidence of gastrointestinal upset, hypotension, or lower limb edema. CONCLUSION Amlodipine with iron chelation therapy significantly improved cardiac parameters, including cardiac-T2 and myocardial iron, in patients with transfusion-dependent thalassemia without causing significant adverse events but enhancing the efficacy of iron chelation therapy.
No takes yet. Share an insight, caveat, or question.
Safwan et al. (2025) conducted a meta-analysis in Transfusion-dependent thalassemia with iron overload (n=144). Amlodipine vs. Standard iron chelation therapy alone or with placebo/spirulina was evaluated on Cardiac T2 (WMD 2.79 ms, 95% CI 0.34-5.24, p=0.03). Amlodipine combined with iron chelation therapy improved cardiac T2 by 2.79 ms compared to control group.
Synapse has enriched 10 related papers. Consider them for comparative context: